The test detects nine organisms considered to be common causes of endometritis, a condition for which no commercial molecular tests are available.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
The test could someday be used to recommend lifestyle changes in otherwise low-risk women who are on the path to becoming diabetic during pregnancy.
Although the two studies seem to provide conflicting results on the impact of PGS, the "devil's in the details," according to an outside expert.
In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The firm is working on harnessing its ability to assess fetal fraction to develop new methods to predict fetal aneuploidy risks and pregnancy complications.
A manufacturing defect caused the control line on the affected tests to not display, which can cause test results to be misinterpreted as negative for the presence of amniotic fluid.
Clinical research has shown that the assay exhibited 100 percent sensitivity compared to culture-based testing methods, Hologic said.
Myriad said that it will fund the $375 million acquisition with a combination of cash, common stock, and funds from its revolving credit facility.
The portfolio being transferred to Diasource includes a complete line of specialty radioimmunoassays with thyroid, fertility, and salt balance markers.
The researchers detected an average of 56 possible environmental organic acids present in each subject and confirmed the presence of six of them.
Cellmic has developed a series of smartphone-based rapid assay readers with applications in medical, veterinary, food safety, biodefense, and drugs-of-abuse testing.
The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.
Beckman said that its assay completes the reproductive menu for its Access immunoassay systems and provides better operational efficiency for labs.
Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.
Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.
Since purchasing the bioscience unit of Sequenom four years ago, Agena has followed global growth by pushing into more clinical labs in China, as well as Europe.
The financing will be used to hire additional team members and conduct additional studies in fertility science. The firm also launched its $199 fertility test.
The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.